Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroendocrine Tumors | 18 | 2013 | 641 | 2.620 |
Why?
|
Aortic Aneurysm, Abdominal | 23 | 2006 | 1228 | 1.490 |
Why?
|
Receptors, Peptide | 4 | 2012 | 279 | 1.250 |
Why?
|
Radioisotopes | 4 | 2013 | 501 | 0.950 |
Why?
|
Organometallic Compounds | 6 | 2011 | 647 | 0.940 |
Why?
|
Radioimmunodetection | 21 | 2001 | 45 | 0.900 |
Why?
|
Octreotide | 4 | 2013 | 154 | 0.830 |
Why?
|
Embolization, Therapeutic | 14 | 2014 | 1419 | 0.820 |
Why?
|
Gastrointestinal Neoplasms | 8 | 2012 | 955 | 0.810 |
Why?
|
Blood Vessel Prosthesis Implantation | 15 | 2004 | 1425 | 0.790 |
Why?
|
Technetium | 20 | 2001 | 326 | 0.730 |
Why?
|
Lutetium | 2 | 2013 | 38 | 0.710 |
Why?
|
Radiology, Interventional | 4 | 2014 | 477 | 0.670 |
Why?
|
Radiopharmaceuticals | 18 | 2013 | 2682 | 0.660 |
Why?
|
Stents | 14 | 2014 | 3177 | 0.600 |
Why?
|
Liver Neoplasms | 16 | 2022 | 4308 | 0.600 |
Why?
|
Postoperative Complications | 25 | 2016 | 15634 | 0.570 |
Why?
|
Magnetic Resonance Angiography | 19 | 2004 | 1432 | 0.560 |
Why?
|
Angiography | 20 | 2014 | 1597 | 0.550 |
Why?
|
Chemoembolization, Therapeutic | 5 | 2011 | 128 | 0.520 |
Why?
|
Carcinoembryonic Antigen | 11 | 2001 | 335 | 0.500 |
Why?
|
Peripheral Vascular Diseases | 14 | 2003 | 488 | 0.480 |
Why?
|
Tomography, X-Ray Computed | 24 | 2014 | 20600 | 0.470 |
Why?
|
Time Management | 1 | 2014 | 52 | 0.470 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 16 | 2001 | 1130 | 0.460 |
Why?
|
Angioplasty | 6 | 2014 | 356 | 0.460 |
Why?
|
Somatostatin | 5 | 2012 | 447 | 0.450 |
Why?
|
Receptors, Somatostatin | 5 | 2013 | 137 | 0.450 |
Why?
|
Graft Occlusion, Vascular | 6 | 2002 | 537 | 0.450 |
Why?
|
Mesenteric Artery, Inferior | 3 | 2002 | 15 | 0.420 |
Why?
|
Radiography, Interventional | 8 | 2014 | 1122 | 0.420 |
Why?
|
Angiography, Digital Subtraction | 7 | 2006 | 335 | 0.420 |
Why?
|
Positron-Emission Tomography | 9 | 2013 | 6585 | 0.390 |
Why?
|
Fluorides | 1 | 2012 | 134 | 0.380 |
Why?
|
Pancreatic Neoplasms | 9 | 2012 | 5366 | 0.370 |
Why?
|
Faculty | 1 | 2014 | 383 | 0.370 |
Why?
|
Vascular Surgical Procedures | 10 | 2002 | 1489 | 0.370 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2014 | 495 | 0.360 |
Why?
|
Radiology Department, Hospital | 1 | 2014 | 407 | 0.350 |
Why?
|
Fluorine Radioisotopes | 2 | 2012 | 420 | 0.350 |
Why?
|
Chylothorax | 2 | 2014 | 83 | 0.350 |
Why?
|
Diagnostic Imaging | 6 | 2011 | 3535 | 0.340 |
Why?
|
Efficiency, Organizational | 1 | 2014 | 695 | 0.340 |
Why?
|
Expert Testimony | 1 | 2012 | 365 | 0.320 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2010 | 101 | 0.310 |
Why?
|
Prosthesis Failure | 5 | 2006 | 1204 | 0.310 |
Why?
|
Antibodies, Monoclonal | 22 | 2001 | 9185 | 0.310 |
Why?
|
Antibiotics, Antineoplastic | 3 | 2011 | 677 | 0.300 |
Why?
|
Iliac Artery | 6 | 2001 | 343 | 0.300 |
Why?
|
Tomography, Emission-Computed | 13 | 2000 | 1123 | 0.280 |
Why?
|
Gastrointestinal Diseases | 1 | 2014 | 1201 | 0.260 |
Why?
|
Catheterization, Peripheral | 3 | 2004 | 343 | 0.260 |
Why?
|
Doxorubicin | 4 | 2011 | 2224 | 0.250 |
Why?
|
Neoplasm Metastasis | 6 | 2011 | 4908 | 0.250 |
Why?
|
Fluorodeoxyglucose F18 | 8 | 2000 | 2025 | 0.240 |
Why?
|
Lumbosacral Region | 3 | 2003 | 293 | 0.230 |
Why?
|
Antigens, Neoplasm | 4 | 2001 | 1984 | 0.230 |
Why?
|
Needles | 2 | 2005 | 451 | 0.230 |
Why?
|
Leg | 13 | 2003 | 1087 | 0.230 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2757 | 0.220 |
Why?
|
Vena Cava, Inferior | 3 | 2003 | 459 | 0.220 |
Why?
|
Liver Cirrhosis | 5 | 2012 | 1932 | 0.220 |
Why?
|
Thrombectomy | 3 | 2006 | 702 | 0.220 |
Why?
|
Arterial Occlusive Diseases | 6 | 1998 | 749 | 0.210 |
Why?
|
Ultrasonography | 4 | 2014 | 5971 | 0.210 |
Why?
|
Venous Thrombosis | 3 | 2011 | 1304 | 0.210 |
Why?
|
CA-19-9 Antigen | 2 | 2001 | 106 | 0.200 |
Why?
|
Quality Assurance, Health Care | 2 | 2009 | 2165 | 0.190 |
Why?
|
Vena Cava Filters | 2 | 2002 | 261 | 0.190 |
Why?
|
Sodium Pertechnetate Tc 99m | 2 | 1999 | 54 | 0.190 |
Why?
|
Humans | 152 | 2022 | 761098 | 0.180 |
Why?
|
Thoracic Duct | 2 | 2014 | 64 | 0.180 |
Why?
|
Magnetic Resonance Imaging | 21 | 2014 | 36418 | 0.170 |
Why?
|
Software | 1 | 2014 | 4433 | 0.170 |
Why?
|
Radiosurgery | 2 | 2012 | 1339 | 0.170 |
Why?
|
Middle Aged | 72 | 2016 | 220835 | 0.170 |
Why?
|
Colorectal Neoplasms | 9 | 2001 | 6919 | 0.170 |
Why?
|
Intraoperative Period | 3 | 2013 | 510 | 0.170 |
Why?
|
Liver | 4 | 2012 | 7513 | 0.160 |
Why?
|
Thrombolytic Therapy | 2 | 2006 | 2055 | 0.160 |
Why?
|
Neoadjuvant Therapy | 1 | 2009 | 2827 | 0.150 |
Why?
|
Aged | 64 | 2022 | 169266 | 0.150 |
Why?
|
Analgesia | 1 | 2022 | 461 | 0.150 |
Why?
|
Anesthesia | 1 | 2009 | 1591 | 0.150 |
Why?
|
Carcinoma, Medullary | 4 | 2006 | 115 | 0.140 |
Why?
|
Punctures | 5 | 2006 | 366 | 0.140 |
Why?
|
Female | 88 | 2016 | 392458 | 0.140 |
Why?
|
Retrospective Studies | 29 | 2022 | 80673 | 0.140 |
Why?
|
Carcinoid Heart Disease | 1 | 2016 | 10 | 0.140 |
Why?
|
Bed Rest | 1 | 1996 | 83 | 0.140 |
Why?
|
Anastomosis, Surgical | 1 | 2000 | 982 | 0.130 |
Why?
|
Contrast Media | 10 | 2005 | 5311 | 0.130 |
Why?
|
Angioplasty, Balloon | 4 | 2001 | 589 | 0.130 |
Why?
|
Vascular Patency | 8 | 2002 | 911 | 0.130 |
Why?
|
Adult | 61 | 2016 | 221083 | 0.130 |
Why?
|
Nerve Block | 1 | 2022 | 705 | 0.130 |
Why?
|
Aged, 80 and over | 31 | 2016 | 58946 | 0.130 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2004 | 1655 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2000 | 4021 | 0.130 |
Why?
|
Thrombosis | 9 | 2001 | 2944 | 0.130 |
Why?
|
Mouth Neoplasms | 1 | 2000 | 596 | 0.120 |
Why?
|
Hyperinsulinism | 1 | 1998 | 400 | 0.120 |
Why?
|
Male | 77 | 2016 | 360675 | 0.120 |
Why?
|
Radiography | 6 | 2011 | 6975 | 0.120 |
Why?
|
Blood Vessel Prosthesis | 9 | 2004 | 951 | 0.120 |
Why?
|
Cholangiography | 1 | 2014 | 181 | 0.120 |
Why?
|
Heart | 4 | 1998 | 4431 | 0.120 |
Why?
|
Antibodies, Antiphospholipid | 1 | 1994 | 71 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2012 | 5667 | 0.120 |
Why?
|
Heart Valves | 1 | 2016 | 284 | 0.120 |
Why?
|
Nephrostomy, Percutaneous | 1 | 2014 | 76 | 0.110 |
Why?
|
Hepatic Artery | 2 | 2011 | 232 | 0.110 |
Why?
|
Adenocarcinoma | 6 | 2001 | 6340 | 0.110 |
Why?
|
Iatrogenic Disease | 2 | 2014 | 539 | 0.110 |
Why?
|
Lymphatic Metastasis | 6 | 2009 | 2913 | 0.110 |
Why?
|
Hypolipidemic Agents | 1 | 1998 | 609 | 0.110 |
Why?
|
Gastrointestinal Hemorrhage | 5 | 2010 | 1116 | 0.110 |
Why?
|
Carcinoma | 3 | 2004 | 2328 | 0.110 |
Why?
|
Sensitivity and Specificity | 19 | 2010 | 14676 | 0.110 |
Why?
|
Immunoconjugates | 1 | 2001 | 963 | 0.110 |
Why?
|
Treatment Outcome | 19 | 2016 | 64670 | 0.110 |
Why?
|
Coronary Disease | 4 | 1998 | 5921 | 0.110 |
Why?
|
Iodine Radioisotopes | 4 | 2006 | 1030 | 0.100 |
Why?
|
Aorta, Abdominal | 3 | 2003 | 625 | 0.100 |
Why?
|
Antiphospholipid Syndrome | 1 | 1994 | 165 | 0.100 |
Why?
|
Pyrazines | 1 | 1998 | 1202 | 0.100 |
Why?
|
Jugular Veins | 2 | 2012 | 210 | 0.100 |
Why?
|
Radionuclide Imaging | 10 | 2000 | 1989 | 0.100 |
Why?
|
Retreatment | 2 | 2006 | 598 | 0.100 |
Why?
|
Endoscopy | 1 | 2002 | 1852 | 0.100 |
Why?
|
Image Enhancement | 5 | 2010 | 2888 | 0.100 |
Why?
|
Catheterization | 6 | 2007 | 1428 | 0.100 |
Why?
|
Follow-Up Studies | 23 | 2005 | 39121 | 0.090 |
Why?
|
Portasystemic Shunt, Surgical | 3 | 1995 | 39 | 0.090 |
Why?
|
Aortography | 2 | 2004 | 421 | 0.090 |
Why?
|
Models, Organizational | 1 | 2014 | 544 | 0.090 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 2010 | 55 | 0.090 |
Why?
|
Prosthesis Design | 5 | 2016 | 2115 | 0.090 |
Why?
|
Pulmonary Embolism | 2 | 2002 | 2571 | 0.090 |
Why?
|
Aortic Aneurysm | 3 | 2002 | 648 | 0.090 |
Why?
|
Multiple Endocrine Neoplasia Type 1 | 1 | 2010 | 43 | 0.090 |
Why?
|
Boston | 2 | 2014 | 9324 | 0.090 |
Why?
|
Catheters, Indwelling | 3 | 1998 | 426 | 0.090 |
Why?
|
Uterine Artery Embolization | 1 | 2010 | 59 | 0.090 |
Why?
|
Models, Economic | 1 | 2014 | 714 | 0.090 |
Why?
|
Practice Guidelines as Topic | 3 | 2014 | 7400 | 0.090 |
Why?
|
Postpartum Hemorrhage | 2 | 2010 | 272 | 0.080 |
Why?
|
von Hippel-Lindau Disease | 1 | 2010 | 151 | 0.080 |
Why?
|
Carcinoid Tumor | 1 | 2011 | 224 | 0.080 |
Why?
|
Kidney Failure, Chronic | 1 | 2001 | 2478 | 0.080 |
Why?
|
Renal Artery Obstruction | 3 | 1999 | 218 | 0.080 |
Why?
|
Phlebography | 5 | 2003 | 326 | 0.080 |
Why?
|
History, 21st Century | 1 | 2014 | 1566 | 0.080 |
Why?
|
Workload | 1 | 2014 | 844 | 0.080 |
Why?
|
Heart Valve Diseases | 1 | 2016 | 1030 | 0.080 |
Why?
|
Blood Pressure | 2 | 2001 | 8478 | 0.080 |
Why?
|
Head and Neck Neoplasms | 4 | 1996 | 2896 | 0.070 |
Why?
|
Radiometry | 2 | 2011 | 812 | 0.070 |
Why?
|
Reference Standards | 1 | 2011 | 1005 | 0.070 |
Why?
|
3-Iodobenzylguanidine | 2 | 2006 | 115 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2012 | 13382 | 0.070 |
Why?
|
Femoral Artery | 5 | 2001 | 826 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 1994 | 938 | 0.070 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2007 | 68 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2001 | 9278 | 0.070 |
Why?
|
Postphlebitic Syndrome | 1 | 2006 | 1 | 0.070 |
Why?
|
Gadolinium | 5 | 2003 | 961 | 0.070 |
Why?
|
Subtraction Technique | 1 | 2010 | 518 | 0.070 |
Why?
|
ACTH Syndrome, Ectopic | 1 | 2006 | 30 | 0.070 |
Why?
|
Hemostasis, Surgical | 1 | 2007 | 126 | 0.070 |
Why?
|
History, 20th Century | 1 | 2014 | 2764 | 0.070 |
Why?
|
Popliteal Vein | 1 | 2006 | 43 | 0.070 |
Why?
|
Intermittent Claudication | 1 | 2008 | 304 | 0.070 |
Why?
|
Physician Assistants | 1 | 2008 | 190 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2009 | 8519 | 0.070 |
Why?
|
Iohexol | 2 | 2005 | 205 | 0.060 |
Why?
|
Pheochromocytoma | 2 | 2006 | 328 | 0.060 |
Why?
|
Professional Role | 1 | 2008 | 313 | 0.060 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2016 | 1554 | 0.060 |
Why?
|
Income | 1 | 2014 | 1868 | 0.060 |
Why?
|
CA-125 Antigen | 3 | 1997 | 276 | 0.060 |
Why?
|
Catecholamines | 1 | 2006 | 387 | 0.060 |
Why?
|
Thyroid Neoplasms | 5 | 2006 | 2331 | 0.060 |
Why?
|
Biological Transport | 1 | 2010 | 2082 | 0.060 |
Why?
|
Neuroblastoma | 2 | 2006 | 1246 | 0.060 |
Why?
|
Mesenteric Artery, Superior | 3 | 2000 | 96 | 0.060 |
Why?
|
Adhesives | 1 | 2005 | 66 | 0.060 |
Why?
|
Thrombophlebitis | 3 | 1997 | 289 | 0.060 |
Why?
|
Indium Radioisotopes | 4 | 1998 | 113 | 0.060 |
Why?
|
Renal Dialysis | 4 | 1998 | 1796 | 0.060 |
Why?
|
Chest Tubes | 1 | 2005 | 152 | 0.060 |
Why?
|
Lymphography | 1 | 2005 | 188 | 0.060 |
Why?
|
Coronary Angiography | 1 | 1996 | 4506 | 0.060 |
Why?
|
Paraganglioma | 1 | 2006 | 143 | 0.060 |
Why?
|
Obstetric Labor Complications | 1 | 2007 | 236 | 0.060 |
Why?
|
Aortic Aneurysm, Thoracic | 2 | 2001 | 695 | 0.060 |
Why?
|
Antibodies, Anti-Idiotypic | 2 | 1996 | 355 | 0.060 |
Why?
|
Predictive Value of Tests | 8 | 2002 | 15308 | 0.060 |
Why?
|
Survival Analysis | 5 | 2011 | 10083 | 0.060 |
Why?
|
False Negative Reactions | 3 | 2000 | 573 | 0.060 |
Why?
|
Neoplasm Staging | 10 | 2000 | 11118 | 0.060 |
Why?
|
Survival Rate | 5 | 2012 | 12727 | 0.060 |
Why?
|
Lymphatic System | 1 | 2005 | 253 | 0.060 |
Why?
|
Prospective Studies | 18 | 2001 | 54419 | 0.060 |
Why?
|
Aorta | 4 | 2004 | 2040 | 0.050 |
Why?
|
Time Factors | 10 | 2016 | 39953 | 0.050 |
Why?
|
False Positive Reactions | 3 | 2000 | 958 | 0.050 |
Why?
|
gamma-Glutamyltransferase | 2 | 1994 | 144 | 0.050 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2006 | 732 | 0.050 |
Why?
|
Quality Control | 1 | 2004 | 834 | 0.050 |
Why?
|
Mucins | 2 | 1995 | 569 | 0.050 |
Why?
|
Veins | 2 | 2003 | 767 | 0.050 |
Why?
|
Heart Diseases | 1 | 1994 | 2795 | 0.050 |
Why?
|
Bone Neoplasms | 2 | 2007 | 2527 | 0.050 |
Why?
|
Incidence | 4 | 2012 | 21357 | 0.050 |
Why?
|
Liver Abscess | 1 | 2001 | 81 | 0.050 |
Why?
|
Oxides | 1 | 2003 | 401 | 0.050 |
Why?
|
Pelvis | 3 | 1999 | 734 | 0.050 |
Why?
|
Midazolam | 1 | 2022 | 267 | 0.050 |
Why?
|
Antibodies, Heterophile | 1 | 2001 | 128 | 0.050 |
Why?
|
Disease Progression | 4 | 2016 | 13506 | 0.050 |
Why?
|
Saphenous Vein | 2 | 1994 | 516 | 0.050 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2001 | 172 | 0.050 |
Why?
|
Lower Extremity | 1 | 2008 | 1201 | 0.040 |
Why?
|
Device Removal | 1 | 2005 | 630 | 0.040 |
Why?
|
Evaluation Studies as Topic | 3 | 1999 | 1624 | 0.040 |
Why?
|
Balloon Occlusion | 1 | 2001 | 125 | 0.040 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2000 | 23 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2007 | 2898 | 0.040 |
Why?
|
Radiotherapy | 1 | 2007 | 1498 | 0.040 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 1994 | 445 | 0.040 |
Why?
|
Arteries | 3 | 2002 | 1121 | 0.040 |
Why?
|
Ischemia | 3 | 1998 | 1889 | 0.040 |
Why?
|
Polytetrafluoroethylene | 1 | 2001 | 245 | 0.040 |
Why?
|
Reproducibility of Results | 5 | 2010 | 20120 | 0.040 |
Why?
|
Esophageal and Gastric Varices | 3 | 1996 | 208 | 0.040 |
Why?
|
Fentanyl | 1 | 2022 | 433 | 0.040 |
Why?
|
Imaging, Three-Dimensional | 3 | 2002 | 4060 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2009 | 3461 | 0.040 |
Why?
|
Algorithms | 3 | 2014 | 14023 | 0.040 |
Why?
|
Thallium Radioisotopes | 2 | 1998 | 139 | 0.040 |
Why?
|
Hepatic Veins | 2 | 1996 | 112 | 0.040 |
Why?
|
Patient Selection | 2 | 2001 | 4245 | 0.040 |
Why?
|
Whole-Body Counting | 4 | 1999 | 36 | 0.040 |
Why?
|
Cerebral Angiography | 1 | 2004 | 1281 | 0.040 |
Why?
|
Collateral Circulation | 1 | 2000 | 293 | 0.040 |
Why?
|
Sigmoid Neoplasms | 1 | 1999 | 53 | 0.040 |
Why?
|
Jejunostomy | 1 | 1998 | 59 | 0.040 |
Why?
|
S100 Proteins | 1 | 1999 | 216 | 0.040 |
Why?
|
Regional Blood Flow | 2 | 2000 | 1498 | 0.040 |
Why?
|
Extremities | 2 | 2002 | 867 | 0.040 |
Why?
|
Cesarean Section | 1 | 2007 | 1396 | 0.040 |
Why?
|
Myocardial Stunning | 1 | 1998 | 67 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 3 | 1999 | 2293 | 0.040 |
Why?
|
Bone Marrow Neoplasms | 1 | 1999 | 101 | 0.040 |
Why?
|
Glucose Clamp Technique | 1 | 1998 | 262 | 0.040 |
Why?
|
Digestive System Neoplasms | 1 | 1998 | 83 | 0.040 |
Why?
|
Arteriovenous Malformations | 1 | 2001 | 396 | 0.040 |
Why?
|
Ultrasonography, Interventional | 1 | 2006 | 1496 | 0.040 |
Why?
|
Aneurysm | 1 | 2001 | 337 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 1983 | 1624 | 0.040 |
Why?
|
Creatinine | 2 | 2001 | 1897 | 0.040 |
Why?
|
Young Adult | 4 | 2011 | 59199 | 0.040 |
Why?
|
Risk Factors | 9 | 2016 | 74219 | 0.040 |
Why?
|
Radiology | 1 | 2011 | 2114 | 0.040 |
Why?
|
Renal Artery | 2 | 1999 | 351 | 0.040 |
Why?
|
Foot Diseases | 1 | 1998 | 148 | 0.040 |
Why?
|
Varicocele | 1 | 1997 | 75 | 0.040 |
Why?
|
Liver Failure | 2 | 1999 | 250 | 0.040 |
Why?
|
Portography | 1 | 1996 | 11 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 2001 | 422 | 0.030 |
Why?
|
Sperm Count | 1 | 1997 | 229 | 0.030 |
Why?
|
Mitomycin | 3 | 2004 | 263 | 0.030 |
Why?
|
Mercaptoethylamines | 1 | 1996 | 4 | 0.030 |
Why?
|
Infusions, Intravenous | 2 | 1998 | 2217 | 0.030 |
Why?
|
Immunoglobulin G | 2 | 2001 | 4538 | 0.030 |
Why?
|
Hypertension, Renovascular | 2 | 1994 | 115 | 0.030 |
Why?
|
Sperm Motility | 1 | 1997 | 266 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 1998 | 627 | 0.030 |
Why?
|
Succinimides | 1 | 1996 | 81 | 0.030 |
Why?
|
Ovarian Neoplasms | 4 | 1997 | 4853 | 0.030 |
Why?
|
Iodobenzenes | 1 | 1995 | 23 | 0.030 |
Why?
|
Pyrrolidines | 1 | 1997 | 339 | 0.030 |
Why?
|
Treatment Failure | 1 | 2002 | 2643 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2009 | 2751 | 0.030 |
Why?
|
Liver Diseases | 2 | 1987 | 1300 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2001 | 791 | 0.030 |
Why?
|
Pilot Projects | 3 | 2012 | 8639 | 0.030 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1996 | 96 | 0.030 |
Why?
|
Pulmonary Veins | 1 | 2001 | 743 | 0.030 |
Why?
|
Pulmonary Artery | 2 | 2001 | 1927 | 0.030 |
Why?
|
Aorta, Thoracic | 1 | 2001 | 1096 | 0.030 |
Why?
|
Catheterization, Central Venous | 2 | 1998 | 526 | 0.030 |
Why?
|
Receptors, Dopamine D2 | 1 | 1997 | 485 | 0.030 |
Why?
|
Organotechnetium Compounds | 1 | 1994 | 132 | 0.030 |
Why?
|
Epitopes | 1 | 2001 | 2503 | 0.030 |
Why?
|
Species Specificity | 1 | 1999 | 2406 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2000 | 1269 | 0.030 |
Why?
|
Liver Cirrhosis, Alcoholic | 2 | 1995 | 64 | 0.030 |
Why?
|
Intraoperative Complications | 1 | 2001 | 1165 | 0.030 |
Why?
|
Infertility, Male | 1 | 1997 | 396 | 0.030 |
Why?
|
Iron | 1 | 2003 | 1790 | 0.030 |
Why?
|
Autoradiography | 1 | 1995 | 729 | 0.030 |
Why?
|
Hypertension, Portal | 1 | 1996 | 227 | 0.030 |
Why?
|
Hepatic Encephalopathy | 1 | 1995 | 143 | 0.030 |
Why?
|
Mesenteric Vascular Occlusion | 1 | 1994 | 92 | 0.030 |
Why?
|
Atherectomy, Coronary | 1 | 1994 | 137 | 0.030 |
Why?
|
Sex Characteristics | 2 | 2001 | 2638 | 0.030 |
Why?
|
Carotid Stenosis | 1 | 2001 | 859 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 1999 | 1008 | 0.030 |
Why?
|
Fibrin | 1 | 1996 | 507 | 0.030 |
Why?
|
Pentetic Acid | 2 | 1998 | 209 | 0.030 |
Why?
|
Warfarin | 1 | 2002 | 1482 | 0.030 |
Why?
|
Mice | 9 | 2001 | 81324 | 0.030 |
Why?
|
Diabetic Angiopathies | 1 | 1998 | 805 | 0.030 |
Why?
|
Adenomatous Polyposis Coli | 1 | 1995 | 219 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2001 | 1661 | 0.030 |
Why?
|
Technology Assessment, Biomedical | 1 | 1995 | 306 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2000 | 1051 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 1999 | 1603 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 1994 | 282 | 0.030 |
Why?
|
Isotope Labeling | 2 | 1996 | 393 | 0.030 |
Why?
|
Adenoma | 2 | 2001 | 2159 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 2 | 1990 | 138 | 0.020 |
Why?
|
Colon | 1 | 2000 | 1791 | 0.020 |
Why?
|
Focal Infection | 1 | 1991 | 9 | 0.020 |
Why?
|
Tissue Distribution | 4 | 1997 | 2262 | 0.020 |
Why?
|
Benzamides | 1 | 1997 | 1370 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1999 | 1378 | 0.020 |
Why?
|
Vascular Diseases | 1 | 1999 | 1160 | 0.020 |
Why?
|
Breast Neoplasms | 4 | 2004 | 20981 | 0.020 |
Why?
|
Gallium Radioisotopes | 1 | 2012 | 195 | 0.020 |
Why?
|
Safety | 3 | 2003 | 1151 | 0.020 |
Why?
|
Cisplatin | 3 | 2004 | 1651 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2004 | 9001 | 0.020 |
Why?
|
Remission Induction | 3 | 2004 | 2392 | 0.020 |
Why?
|
Adenoma, Islet Cell | 1 | 2010 | 72 | 0.020 |
Why?
|
Thromboembolism | 1 | 1997 | 993 | 0.020 |
Why?
|
Ethiodized Oil | 2 | 2001 | 26 | 0.020 |
Why?
|
Monitoring, Intraoperative | 1 | 1997 | 943 | 0.020 |
Why?
|
Administration, Oral | 1 | 1998 | 4014 | 0.020 |
Why?
|
Blood Vessels | 2 | 1993 | 1111 | 0.020 |
Why?
|
Peritoneovenous Shunt | 1 | 1989 | 9 | 0.020 |
Why?
|
Melanoma | 2 | 1999 | 5694 | 0.020 |
Why?
|
Rectal Neoplasms | 1 | 1999 | 1156 | 0.020 |
Why?
|
Polyvinyl Alcohol | 2 | 2001 | 73 | 0.020 |
Why?
|
Animals | 12 | 2001 | 168083 | 0.020 |
Why?
|
Nerve Regeneration | 1 | 1995 | 796 | 0.020 |
Why?
|
Odds Ratio | 1 | 2002 | 9648 | 0.020 |
Why?
|
Stomach Neoplasms | 3 | 1998 | 1458 | 0.020 |
Why?
|
Adolescent | 7 | 2010 | 88271 | 0.020 |
Why?
|
Logistic Models | 3 | 2002 | 13254 | 0.020 |
Why?
|
alpha-Fetoproteins | 2 | 1999 | 223 | 0.020 |
Why?
|
Job Description | 1 | 2008 | 59 | 0.020 |
Why?
|
Bone Marrow | 1 | 1999 | 2911 | 0.020 |
Why?
|
Education, Professional | 1 | 2008 | 52 | 0.020 |
Why?
|
Germany | 1 | 2010 | 872 | 0.020 |
Why?
|
United States | 6 | 2011 | 72337 | 0.020 |
Why?
|
Technetium Tc 99m Dimercaptosuccinic Acid | 2 | 1998 | 81 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 3882 | 0.020 |
Why?
|
Hemostatics | 1 | 2010 | 240 | 0.020 |
Why?
|
Ascites | 1 | 1989 | 338 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5070 | 0.020 |
Why?
|
Heart Valve Prosthesis | 1 | 2016 | 1463 | 0.020 |
Why?
|
Thallium | 1 | 1987 | 100 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 1991 | 518 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3803 | 0.020 |
Why?
|
Coronary Vessels | 2 | 1999 | 3111 | 0.020 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 1994 | 1724 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1999 | 2528 | 0.020 |
Why?
|
Phantoms, Imaging | 1 | 1995 | 2515 | 0.020 |
Why?
|
Anticoagulants | 1 | 2002 | 4795 | 0.020 |
Why?
|
Costs and Cost Analysis | 3 | 1998 | 1664 | 0.020 |
Why?
|
Kidney Neoplasms | 2 | 1994 | 4251 | 0.020 |
Why?
|
Preoperative Care | 4 | 1998 | 2242 | 0.020 |
Why?
|
Ambulatory Care | 1 | 1996 | 2769 | 0.020 |
Why?
|
Accreditation | 1 | 2008 | 473 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 1743 | 0.020 |
Why?
|
Half-Life | 2 | 1997 | 649 | 0.020 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2008 | 385 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 1995 | 2000 | 0.010 |
Why?
|
Government Regulation | 1 | 2008 | 524 | 0.010 |
Why?
|
Gamma Cameras | 2 | 1995 | 35 | 0.010 |
Why?
|
Radioimmunoassay | 2 | 1999 | 861 | 0.010 |
Why?
|
Insulin | 1 | 1998 | 6588 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1998 | 3416 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2001 | 15845 | 0.010 |
Why?
|
Fee-for-Service Plans | 1 | 2008 | 698 | 0.010 |
Why?
|
Echocardiography | 1 | 2016 | 5006 | 0.010 |
Why?
|
Parkinson Disease | 1 | 1997 | 2869 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 1997 | 694 | 0.010 |
Why?
|
Surface Properties | 2 | 1996 | 1162 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1472 | 0.010 |
Why?
|
Germ-Line Mutation | 1 | 2010 | 1852 | 0.010 |
Why?
|
Child | 2 | 2010 | 80134 | 0.010 |
Why?
|
Cause of Death | 2 | 2004 | 3688 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 1994 | 3594 | 0.010 |
Why?
|
Heart Transplantation | 1 | 1995 | 3258 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 1999 | 11732 | 0.010 |
Why?
|
Ferrosoferric Oxide | 1 | 2003 | 348 | 0.010 |
Why?
|
ROC Curve | 2 | 2003 | 3582 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6067 | 0.010 |
Why?
|
Magnetite Nanoparticles | 1 | 2003 | 316 | 0.010 |
Why?
|
Equipment Safety | 1 | 2002 | 249 | 0.010 |
Why?
|
Equipment Design | 2 | 2001 | 3509 | 0.010 |
Why?
|
Dextrans | 1 | 2003 | 574 | 0.010 |
Why?
|
Silicon | 1 | 2001 | 142 | 0.010 |
Why?
|
Observer Variation | 2 | 1999 | 2611 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1376 | 0.010 |
Why?
|
Cost-Benefit Analysis | 2 | 2008 | 5494 | 0.010 |
Why?
|
Constriction, Pathologic | 2 | 1994 | 1097 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 2 | 1994 | 3163 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2003 | 10755 | 0.010 |
Why?
|
Models, Biological | 2 | 1997 | 9455 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1999 | 5809 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4739 | 0.010 |
Why?
|
Polyethylene Terephthalates | 1 | 1999 | 112 | 0.010 |
Why?
|
Exercise Test | 1 | 1987 | 2165 | 0.010 |
Why?
|
Air | 1 | 1999 | 187 | 0.010 |
Why?
|
Thymidine Kinase | 1 | 1999 | 286 | 0.010 |
Why?
|
Technetium Tc 99m Medronate | 1 | 1999 | 133 | 0.010 |
Why?
|
Gated Blood-Pool Imaging | 1 | 1998 | 44 | 0.010 |
Why?
|
Mice, Nude | 2 | 1995 | 3604 | 0.010 |
Why?
|
Feasibility Studies | 2 | 2000 | 5249 | 0.010 |
Why?
|
Leukocytosis | 1 | 1999 | 251 | 0.010 |
Why?
|
Perfusion | 2 | 1994 | 1390 | 0.010 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 1998 | 198 | 0.010 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 1998 | 183 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1990 | 2223 | 0.010 |
Why?
|
Luminescent Measurements | 1 | 1999 | 340 | 0.010 |
Why?
|
Hormones, Ectopic | 1 | 1997 | 37 | 0.010 |
Why?
|
Congresses as Topic | 1 | 2002 | 803 | 0.010 |
Why?
|
Palpation | 1 | 1997 | 166 | 0.010 |
Why?
|
Ligation | 1 | 1997 | 446 | 0.010 |
Why?
|
Antiparkinson Agents | 1 | 1997 | 184 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 2 | 1994 | 782 | 0.010 |
Why?
|
Hemorheology | 1 | 1996 | 144 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3450 | 0.010 |
Why?
|
Iliac Vein | 1 | 1996 | 70 | 0.010 |
Why?
|
Immunoassay | 1 | 1999 | 743 | 0.010 |
Why?
|
Thymus Neoplasms | 1 | 1998 | 274 | 0.010 |
Why?
|
Gadolinium DTPA | 1 | 1999 | 823 | 0.010 |
Why?
|
Equipment Failure | 1 | 1998 | 579 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2001 | 3419 | 0.010 |
Why?
|
Genetic Variation | 1 | 2010 | 6565 | 0.010 |
Why?
|
Carotid Arteries | 1 | 1999 | 941 | 0.010 |
Why?
|
Rheology | 1 | 1996 | 347 | 0.010 |
Why?
|
Suction | 1 | 1996 | 266 | 0.010 |
Why?
|
Medicaid | 1 | 2008 | 2814 | 0.010 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 1995 | 317 | 0.010 |
Why?
|
Diatrizoate | 1 | 1994 | 81 | 0.010 |
Why?
|
Artifacts | 2 | 1993 | 1913 | 0.010 |
Why?
|
Hypertrophy | 1 | 1996 | 558 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1996 | 239 | 0.010 |
Why?
|
Basal Ganglia | 1 | 1997 | 554 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1998 | 767 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 1998 | 12145 | 0.010 |
Why?
|
Life Tables | 1 | 1994 | 364 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2001 | 1118 | 0.010 |
Why?
|
Blood | 1 | 1996 | 596 | 0.010 |
Why?
|
Microvilli | 1 | 1994 | 234 | 0.010 |
Why?
|
Prevalence | 1 | 2010 | 15717 | 0.010 |
Why?
|
Abdomen | 1 | 1999 | 1128 | 0.010 |
Why?
|
Length of Stay | 2 | 2002 | 6420 | 0.010 |
Why?
|
Portal Vein | 1 | 1995 | 432 | 0.010 |
Why?
|
Gastrointestinal Agents | 1 | 1998 | 510 | 0.010 |
Why?
|
Recurrence | 2 | 1996 | 8456 | 0.010 |
Why?
|
Forecasting | 1 | 2001 | 2928 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 1994 | 217 | 0.010 |
Why?
|
Fever | 1 | 1999 | 1618 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1994 | 1057 | 0.010 |
Why?
|
Pulsatile Flow | 1 | 1992 | 320 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 1999 | 3591 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1994 | 1703 | 0.010 |
Why?
|
Extracorporeal Circulation | 1 | 1992 | 181 | 0.010 |
Why?
|
Popliteal Artery | 1 | 1993 | 310 | 0.010 |
Why?
|
Pregnancy | 2 | 2007 | 29872 | 0.010 |
Why?
|
Fibrosis | 1 | 1998 | 2051 | 0.010 |
Why?
|
Reference Values | 1 | 1998 | 4922 | 0.010 |
Why?
|
Frontal Lobe | 1 | 1997 | 1417 | 0.010 |
Why?
|
Medicare | 1 | 2008 | 6775 | 0.010 |
Why?
|
Prognosis | 1 | 1991 | 29672 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1991 | 2087 | 0.010 |
Why?
|
Hemodynamics | 1 | 2000 | 4164 | 0.010 |
Why?
|
Kidney Tubules, Proximal | 1 | 1992 | 382 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2003 | 12341 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1999 | 2914 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 1999 | 6817 | 0.000 |
Why?
|
Postoperative Period | 1 | 1994 | 1818 | 0.000 |
Why?
|
Radiation Dosage | 1 | 1997 | 1966 | 0.000 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12058 | 0.000 |
Why?
|
Antineoplastic Agents | 2 | 2004 | 13630 | 0.000 |
Why?
|
Membrane Glycoproteins | 1 | 1999 | 3696 | 0.000 |
Why?
|
Sex Factors | 1 | 2001 | 10552 | 0.000 |
Why?
|
Patient Readmission | 1 | 2002 | 3268 | 0.000 |
Why?
|
Rats | 2 | 1996 | 23713 | 0.000 |
Why?
|
Biopsy | 1 | 1999 | 6781 | 0.000 |
Why?
|
Reoperation | 1 | 1997 | 4304 | 0.000 |
Why?
|
Comorbidity | 1 | 2001 | 10514 | 0.000 |
Why?
|
Transplantation, Heterologous | 1 | 1994 | 2381 | 0.000 |
Why?
|
Rabbits | 1 | 1992 | 4749 | 0.000 |
Why?
|
Coronary Artery Bypass | 1 | 1994 | 2193 | 0.000 |
Why?
|
Myocardium | 1 | 1998 | 4746 | 0.000 |
Why?
|
Random Allocation | 1 | 1989 | 2393 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1994 | 6198 | 0.000 |
Why?
|
Regression Analysis | 1 | 1994 | 6343 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1996 | 8164 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2002 | 22157 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1999 | 8000 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1999 | 8529 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 2004 | 9025 | 0.000 |
Why?
|
Immunotherapy | 1 | 1996 | 4642 | 0.000 |
Why?
|
Risk Assessment | 1 | 2001 | 24013 | 0.000 |
Why?
|
Neoplasms | 1 | 1987 | 22125 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1992 | 11066 | 0.000 |
Why?
|
Myocardial Infarction | 1 | 1998 | 11475 | 0.000 |
Why?
|
Kidney | 1 | 1992 | 7034 | 0.000 |
Why?
|
Cohort Studies | 1 | 1996 | 41486 | 0.000 |
Why?
|
Quality of Life | 1 | 1995 | 13362 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1987 | 12975 | 0.000 |
Why?
|